Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy

Chan Cheah, TE Lew, D A A Carney, H Miles Prince, M Wolf, A Bazargan, EH Januszewicz, R Filshie, D Westerman, JF Seymour, CS Tam

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Despite its efficacy in prospective trials, full dose fludarabine, cyclophosphamide and rituximab (FCR) may be too toxic for elderly patients with chronic lymphocytic leukemia (CLL) in clinical practice. We retrospectively reviewed the impact of dose reductions in FCR therapy on the outcomes of 42 consecutive patients aged 65-87 (median 72) years. Despite a median cumulative fludarabine dose reduction of 50% from full dose, the objective response and complete response rates were 86% and 38% respectively (frontline 94%/59%; previously treated 80%/24%). Dose reductions of 25-75% were not significantly associated with inferior progression free survival compared to minimal reductions (≤25%) (p = 0.49), and did not preclude deep responses, including six cases (14%) of minimal residual disease negativity. Although hematological and infectious toxicities were common, treatment limiting adverse effects were infrequent. Dose attenuated FCR appears to have preserved efficacy and may be a viable therapeutic option for elderly patients with CLL. © 2015 Taylor and Francis.
Original languageEnglish
Pages (from-to)1044-1053
Number of pages10
JournalLEUKEMIA & LYMPHOMA
Volume57
Issue number5
Publication statusPublished - 3 May 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy'. Together they form a unique fingerprint.

Cite this